AVANIR PHARMACEUTICALS, INC.
DelistedCIK 858803fmd_02TH40JH6WXVWVFFPD7R8EN0WKManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Oct 01, 2008 to Sep 30, 2014, 19 periods
Latest annual · FY2014
Millions- Total revenues
- 115
- Gross profit
- 112
- Operating income
- (46)
- Net income
- (50)
- Free cash flow
- (52)
Latest quarter · Q4 FY2014
Millions- Total revenues
- 33
- Gross profit
- 34
- Operating income
- (13)
- Net income
- (14)
- Free cash flow
- (8)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2011 to FY2014
- +122.1%
- Revenue, 5 yearsFY2009 to FY2014
- n/m
- Net income, 5 yearsFY2009 to FY2014
- n/m
AVANIR PHARMACEUTICALS, INC. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2014 | FY2013 | Change | Source |
|---|---|---|---|---|
| Revenue | $115 million | $75.4 million | +52.6% | 10-K 2014-12-10 · proof |
| Gross profit | $111.7 million | $71.4 million | +56.5% | 10-K 2014-12-10 · proof |
| Operating income | -$46.3 million | -$71.4 million | 10-K 2014-12-10 · proof | |
| Net income | -$50.4 million | -$75.5 million | 10-K 2014-12-10 · proof | |
| Cash from operating activities | -$48.7 million | -$65.4 million | 10-K 2014-12-10 · proof | |
| Free cash flow | -$51.7 million | -$65.9 million | 10-K 2014-12-10 · proof | |
| Total assets | $307 million | $76.1 million | +303.5% | 10-K 2014-12-10 · proof |
| Total liabilities | $33.6 million | $57.6 million | -41.7% | 10-K 2014-12-10 · proof |
| Cash and cash equivalents | $271.9 million | $55.3 million | +392% | 10-K 2014-12-10 · proof |
- What was AVANIR PHARMACEUTICALS, INC.'s revenue in fiscal 2014?
- AVANIR PHARMACEUTICALS, INC. reported revenue of $115 million for fiscal 2014 (the year ended Sep 30, 2014), against $75.4 million the year before (+52.6%). Source: the 10-K filed with the SEC on Dec 10, 2014. SEC
- What was AVANIR PHARMACEUTICALS, INC.'s gross profit in fiscal 2014?
- AVANIR PHARMACEUTICALS, INC. reported gross profit of $111.7 million for fiscal 2014 (the year ended Sep 30, 2014), against $71.4 million the year before (+56.5%). Source: the 10-K filed with the SEC on Dec 10, 2014. SEC
- What was AVANIR PHARMACEUTICALS, INC.'s operating income in fiscal 2014?
- AVANIR PHARMACEUTICALS, INC. reported operating income of -$46.3 million for fiscal 2014 (the year ended Sep 30, 2014), against -$71.4 million the year before. Source: the 10-K filed with the SEC on Dec 10, 2014. SEC
- What was AVANIR PHARMACEUTICALS, INC.'s net income in fiscal 2014?
- AVANIR PHARMACEUTICALS, INC. reported net income of -$50.4 million for fiscal 2014 (the year ended Sep 30, 2014), against -$75.5 million the year before. Source: the 10-K filed with the SEC on Dec 10, 2014. SEC
- What was AVANIR PHARMACEUTICALS, INC.'s cash from operating activities in fiscal 2014?
- AVANIR PHARMACEUTICALS, INC. reported cash from operating activities of -$48.7 million for fiscal 2014 (the year ended Sep 30, 2014), against -$65.4 million the year before. Source: the 10-K filed with the SEC on Dec 10, 2014. SEC
- What was AVANIR PHARMACEUTICALS, INC.'s free cash flow in fiscal 2014?
- AVANIR PHARMACEUTICALS, INC. reported free cash flow of -$51.7 million for fiscal 2014 (the year ended Sep 30, 2014), against -$65.9 million the year before. Source: the 10-K filed with the SEC on Dec 10, 2014. SEC
- What are AVANIR PHARMACEUTICALS, INC.'s total assets?
- As of Sep 30, 2014, AVANIR PHARMACEUTICALS, INC. reported total assets of $307 million, against $76.1 million a year earlier (+303.5%). Source: the 10-K filed with the SEC on Dec 10, 2014. SEC
- What are AVANIR PHARMACEUTICALS, INC.'s total liabilities?
- As of Sep 30, 2014, AVANIR PHARMACEUTICALS, INC. reported total liabilities of $33.6 million, against $57.6 million a year earlier (-41.7%). Source: the 10-K filed with the SEC on Dec 10, 2014. SEC
- What are AVANIR PHARMACEUTICALS, INC.'s cash and cash equivalents?
- As of Sep 30, 2014, AVANIR PHARMACEUTICALS, INC. reported cash and cash equivalents of $271.9 million, against $55.3 million a year earlier (+392%). Source: the 10-K filed with the SEC on Dec 10, 2014. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:858803&period_type=annual&limit=5"Information only, not investment advice.